直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Book

The Chemical and Pharmaceutical Innovation Report 2013

December 2, 2013

By Adriana L. Burgy; Shana K. Cyr, Ph.D.; Pier D. DeRoo; Li Feng, Ph.D.; Carla Mouta-Bellum, Ph.D.; Jennifer H. Roscetti

Finnegan is pleased to release The Chemical and Pharmaceutical Innovation Report 2013. The Report 2013 is a complimentary eBook for patent practitioners, entrepreneurs, business executives, venture capitalists, and inventors that benchmarks the patent activities of the U.S. chemical and pharmaceutical industries from 2006 to 2012.

The Report 2013 includes:

  • Litigation trends by technology, issues on appeal, and jurisdiction
  • Analyses of final decisions from U.S. district courts and appellate courts
  • Evolution of certain claim terms across technologies
  • Concise summaries of changes under the America Invents Act (“AIA”)
  • Detailed patent-filing trends for the top fifteen chemical and pharmaceutical companies on the 2012 Fortune 500 list
  • Categorized listing of Federal Circuit decisions from 2006 to 2012

The Chemical and Pharmaceutical Innovation Report 2013 eBook details the chemical and pharmaceutical industries’ patent activities in five sections:

1. Patenting and Application Publication Trends

Examines patent applications and patents granted in the past decade to uncover rising industry activities and tendencies in claim terms, and highlights trends at top chemical and pharmaceutical companies.

2. District Court Litigation Trends

Looks at U.S. district court decisions reached in chemical and pharmaceutical patent cases from 2002 to 2012, compares them to final decisions in other industries, and details those cases by trial type, win rates, and popular jurisdictions. The Report 2013 also compiles statistics for Abbreviated New Drug Application (“ANDA”) cases.

3. Appellate Litigation Trends

Analyzes chemical and pharmaceutical patent decisions at the Federal Circuit from 2010 to 2012, identifies affirmance rates, and details those cases by tribunal and issue.

4. The America Invents Act

Summarizes key considerations for provisions of the historic America Invents Act (“AIA”) that went into effect in March 2013, including first-inventor-to-file and post-grant proceedings.

5. Chemical and Pharmaceutical Federal Circuit Cases from 2006 to 2012

Categorizes chemical and pharmaceutical Federal Circuit decisions from 2006 to 2012, outlining key details in quick-reference charts; also provides case summaries of the most significant chemical and pharmaceutical decisions. The categorization and case summaries highlight not only the type of issue litigated, but also provide insight into the interpretation and application of the patent laws.

Download a complimentary copy of The Report 2013 eBook using the form below. We welcome your comments and inquiries. For a brief overview of the latest trends and findings in the chemical, pharmaceutical, and biotechnological industries, listen to this preview podcast from eBook editor Adriana L. Burgy.

By submitting this form, you agree to Finnegan storing your contact information in our marketing database. Once you submit the form, a link to the book will appear below under Downloadable Files. If you would like to receive other Finnegan insights, please fill out a preferences form here.

Tags

patent application, United States Court of Appeals for the Federal Circuit (CAFC), America Invents Act (AIA)

Downloadable Files

  • TheChemicalandPharmaceuticalInnovationReport2013_FinaleBook

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Patent Office Invalidation Proceedings

Prosecution and Portfolio Management

Patent Drafting and Prosecution

Related Industries

Chemicals, Industrials, and Materials

Chemical

Energy

Life Sciences

Pharmaceutical

Related Professionals

Adriana L. Burgy
Partner
Washington, DC
+1 202 408 4345
Email
Pier D. DeRoo
Partner
Washington, DC
+1 202 408 4418
Email
Li Feng, Ph.D.
Partner
Washington, DC
+1 202 408 4382
Email
Jennifer H. Roscetti
Partner
Washington, DC
+1 202 408 4150
Email

Related Insights

Conference

Georgia Life Sciences Summit 2026

August 25-26, 2026

Sandy Springs

Conference

13th Annual Summit for Women Leaders in Life Sciences Law

July 29-30, 2026

Boston

Conference

2026 China Pharmaceutical Innovation Conference

July 22-24, 2026

Shanghai

Federal Circuit IP Blog

“2” Does Not Provide Written Description Support for “1”: Federal Circuit Affirms District Court’s Invalidation of Patent

July 8, 2026

Federal Circuit IP Blog

Federal Circuit Affirms Noninfringement Ruling in Hatch-Waxman Litigation Based on Claim Construction, Prosecution History Estoppel, and the Disclosure-Dedication Rule

June 26, 2026

Federal Circuit IP Blog

Federal Circuit Affirms Indefiniteness of the Term “About”

June 10, 2026

European IP Blog

UPC Central Division Revokes Patent Covering Covid-19 Treatment Remdesivir

8 June 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP